RxDoctor Payments Data

Ashish Sitapara, MD

Internal Medicine · Newtown, PANPI 1720023971

Payments from drug & device makers

$3,389in general payments, 2019–2025

Across 78 payments — averaging $43.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$991
  • Impulse Dynamics (USA) Inc.$565
  • Novo Nordisk$523
  • Boston Scientific$506
  • GSK$228
  • Heartflow, Inc.$129
  • plus $446 from 7 others

What the payments were for

  • Food & beverage$3,389100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,389 in reported general payments places this provider in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$278,452
Medicare patients
223
Services billed
5,171

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide73$80,417
JardianceEmpagliflozin44$49,212
EliquisApixaban30$36,823
OzempicSemaglutide31$34,004
Breo ElliptaFluticasone/Vilanterol12$6,233
Mesalamine11$4,313
PaxlovidNirmatrelvir/Ritonavir19$2,859
Memantine Hcl ErMemantine Hcl17$1,983
Rosuvastatin Calcium73$1,109
Metoprolol Succinate46$905
Valsartan18$844
SynthroidLevothyroxine Sodium12$836
Atorvastatin Calcium61$770
SotalolSotalol Hcl11$670
Levothyroxine Sodium46$628

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$46$80,41773 claims
PfizerEliquis, Paxlovid$17$39,68249 claims
Novo NordiskOzempic$523$34,00431 claims
GSKBreo Ellipta$228$6,23312 claims
AbbVieSynthroid$43$83612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Newtown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →